Monthly Archives: February 2016

Draghi Strives To Steady The Ship

The start of 2016 has been volatile by any standards, but the trend on major global stock markets is lower. Chief amongst the losers of stock value has been the banking sector – one must remember that markets are often driven by sentiment rather than reason. Many analysts believe that the decline in the value…

Daily Market Analysis – 2/17/2016

Video length: 00:01:39 During the day on Wednesday, we have a ton of economic announcements coming out that could move the market. With that being the case, we expect to see quite a bit of volatility and it’s likely that there will be a massive amount of trading opportunities out there. 1 – We still…

It’s About Time: Smart Money Finally Nibbling At Pipeline MLPs

Midstream oil and gas pipeline MLPs have been just about the most despised asset class in recent memory. Yes they just got a major shot in the arm from two legendary investors, Warren Buffett and David Tepper. Buffett’s Berkshire Hathway (BRK-A) just disclosed today that it accumulated 26.5 million shares at an average price of $23.72, putting his…

Iran Opts Out Of Oil Freeze Agreement

Four major oil producing countries–Qatar, Saudi Arabia, Russia and Venezuela– agreed Tuesday to lead an effort to freeze oil output at January levels but held back from announcing a cut in production of the crude. Oil producer Iran quickly pulled back from a deal saying it would not abandon its share in the oil market,…

Large Cap Biopharma Winners And Losers 2015-16: Which Stocks Can

<< Read Large Cap Biopharma Winners and Losers Part 1   Rayno Large Cap Biopharmaceuticals…Part 2…A Stock pickers Market Time to Rebuild Your Portfolio: ABBV, BMY, GILD Below we have summarized selective metrics for large cap biopharmaceutical companies. We began the process of revising and rebalancing our portfolio after the J.P.Morgan Healthcare Conference. Here are some…

E

Shares of Flexion Therapeutics (FLXN) soared 28% in after-hours trade on Tuesday after it had announced that its phase 3 trial hit the primary endpoint of the study. The phase 3 trial recruited 486 patients and split them up into three different dose groups. One group of patients took a single IA injection of 40 mg…

Market Outlook For 2016

The past seven years since the financial crisis have seen the S&P 500 bounce back by 150%, even as GDP growth continues to be slow. Digging deeper, stagnant wages and extremely low productivity growth show that the real economy has not kept pace with Wall Street. Inevitably, that gap was going to have to close, and I…

Just A Dead Cat Bounce?

Well, maybe so. Was there any news to stimulate this action Tuesday? Hmm, oil down? Yep. Economic data weak again? Yep, but you may be into that bad-news-is-good nonsense. Let’s see, Empire State Mfg Survey -16.64 vs -10 expected & prior -19.37 isn’t good unless you’re into, it could’ve been worse; and, Homebuilders Sentiment falls again to…